{"disease":{"id":"adenosine-deaminase-deficiency","name":"Adenosine deaminase deficiency","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":3,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"elapegademase","indication_name":"Adenosine deaminase severe combined immune deficiency (ADA-SCID)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Revcovi","generic_name":"ELAPEGADEMASE","company_name":"Leadiant Biosci Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":44,"revenue":null,"mechanism":"Revcovi works by replacing the deficient enzyme adenosine deaminase, allowing the body to break down toxic substances."},{"drug_id":"elapegademase","indication_name":"Adenosine deaminase deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Revcovi","generic_name":"ELAPEGADEMASE","company_name":"Leadiant Biosci Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":44,"revenue":null,"mechanism":"Revcovi works by replacing the deficient enzyme adenosine deaminase, allowing the body to break down toxic substances."},{"drug_id":"adagen","indication_name":"Adenosine deaminase deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Adagen","company_name":"Leadiant Biosciences, Inc.","drug_phase":"phase_3","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":null},{"drug_id":"pegademase","indication_name":"Adenosine deaminase deficiency","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"pegademase","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03655223","title":"Early Check: Expanded Screening in Newborns","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT05300334","title":"Investigation of ADA Enzyme Deficiency","phase":"","overall_status":"UNKNOWN","enrollment_count":800,"lead_sponsor_name":"TRPHARM","has_results":false},{"nct_id":"NCT05300347","title":"Observational Study Evaluating the Prevalence of Enzyme Deficiency in Pulmonology Clinics (ADA)","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"TRPHARM","has_results":false},{"nct_id":"NCT05300373","title":"Evaluation of Adenosine Deaminase (ADA) Enzyme Deficiency in Patients With Lymphopenia and/or Elevated Immunoglobulin E","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"TRPHARM","has_results":false},{"nct_id":"NCT01380990","title":"Lentiviral (LV) Gene Therapy for Adenosine Deaminase (ADA) Deficiency","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Great Ormond Street Hospital for Children NHS Foundation Trust","has_results":true},{"nct_id":"NCT03878069","title":"Registry Study of Revcovi Treatment in Patients With ADA-SCID","phase":"","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"Chiesi Farmaceutici S.p.A.","has_results":true},{"nct_id":"NCT05432310","title":"Gene Therapy for Adenosine Deaminase Severe Combined Immune Deficiency Using Peripheral Blood and EFS ADA Vector","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"University of California, Los Angeles","has_results":false},{"nct_id":"NCT03645460","title":"Gene Therapy for ADA-SCID Using an Improved Lentiviral Vector (Ivlv-ADA)","phase":"NA","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"Shenzhen Geno-Immune Medical Institute","has_results":false},{"nct_id":"NCT01420627","title":"EZN-2279 in Patients With ADA-SCID","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":7,"lead_sponsor_name":"Leadiant Biosciences, Inc.","has_results":true},{"nct_id":"NCT00008450","title":"Total-Body Irradiation Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Severe Combined Immunodeficiency Undergoing Donor Bone Marrow Transplant","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT02022696","title":"Treatment of SCID Due to ADA Deficiency With Autologous Transplantation of Cord Blood or Hematopoietic CD 34+ Cells After Addition of a Normal Human ADA cDNA by the EFS-ADA Lentiviral Vector","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":1,"lead_sponsor_name":"National Human Genome Research Institute (NHGRI)","has_results":false}],"total":11},"guidelines":[],"source":"Drug Landscape verified database"}